WO2007112940A3 - Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same - Google Patents
Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same Download PDFInfo
- Publication number
- WO2007112940A3 WO2007112940A3 PCT/EP2007/002817 EP2007002817W WO2007112940A3 WO 2007112940 A3 WO2007112940 A3 WO 2007112940A3 EP 2007002817 W EP2007002817 W EP 2007002817W WO 2007112940 A3 WO2007112940 A3 WO 2007112940A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- albumin
- entities
- life
- amino acid
- therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention relates to albumin-derived amino acid sequences that can be used to increase the half-life of therapeutic proteins and of other therapeutic compounds and entities.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78825606P | 2006-03-31 | 2006-03-31 | |
US60/788,256 | 2006-03-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007112940A2 WO2007112940A2 (en) | 2007-10-11 |
WO2007112940A3 true WO2007112940A3 (en) | 2008-01-03 |
Family
ID=38477256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/002817 WO2007112940A2 (en) | 2006-03-31 | 2007-03-29 | Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2007112940A2 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2731617A1 (en) | 2008-07-22 | 2010-01-28 | Maria Joao Saraiva | Amino acid sequences directed against multitarget scavenger receptors and polypeptides |
IT1392551B1 (en) * | 2008-11-25 | 2012-03-09 | Bioindustry Park Del Canavese S P A | BIOMARCERS FOR DIAGNOSIS AND TO DETECT THE PROGRESSION OF NEURODEGENERATIVE DISEASES, IN PARTICULAR OF AMIOTROPHIC LATERAL SCLEROSIS |
CN102317315A (en) | 2009-02-11 | 2012-01-11 | 诺维信生物制药丹麦公司 | Albumin variants and conjugates |
JP5841046B2 (en) * | 2009-04-08 | 2016-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Human protein scaffold with controlled serum pharmacokinetics |
JP2013509170A (en) | 2009-10-30 | 2013-03-14 | ノボザイムス バイオファーマ デーコー アクティーゼルスカブ | Albumin variant |
WO2011073180A1 (en) | 2009-12-14 | 2011-06-23 | Ablynx N.V. | Single variable domain antibodies against ox40l, constructs and therapeutic use |
WO2011083141A2 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Method for generation of immunoglobulin sequences by using lipoprotein particles |
US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
WO2011124718A1 (en) | 2010-04-09 | 2011-10-13 | Novozymes A/S | Albumin derivatives and variants |
CN102906118B (en) | 2010-05-20 | 2017-07-28 | 埃博灵克斯股份有限公司 | The biomaterial related to HER3 |
JP5933573B2 (en) | 2010-11-08 | 2016-06-15 | ノバルティス アーゲー | CXCR2 binding polypeptide |
RU2650784C2 (en) | 2011-05-05 | 2018-04-17 | Альбумедикс А/С | Versions of albumin |
UA117218C2 (en) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same |
SI2726510T1 (en) | 2011-05-27 | 2023-06-30 | F. Hoffmann - La Roche Ag | Dual targeting |
WO2012163521A1 (en) | 2011-05-27 | 2012-12-06 | Dutalys | Removal of monomeric targets |
EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
KR20140136934A (en) | 2012-03-16 | 2014-12-01 | 노보자임스 바이오파마 디케이 에이/에스 | Albumin variants |
US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
BR112015010318A2 (en) | 2012-11-08 | 2017-08-22 | Albumedix As | ALBUMIN VARIANTS |
CA2989966C (en) | 2015-08-20 | 2024-04-30 | Albumedix A/S | Albumin variants and conjugates |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
KR20200104333A (en) | 2017-12-28 | 2020-09-03 | 난징 레전드 바이오테크 씨오., 엘티디. | Single-domain antibodies to TIGIT and variants thereof |
CA3084518A1 (en) | 2018-01-15 | 2019-07-18 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against pd-1 |
US11958903B2 (en) | 2018-03-30 | 2024-04-16 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against LAG-3 and uses thereof |
CN110988361B (en) * | 2019-12-13 | 2020-09-18 | 山东民康生物科技有限公司 | Human serum albumin removing kit |
WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003060071A2 (en) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2004041863A2 (en) * | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
-
2007
- 2007-03-29 WO PCT/EP2007/002817 patent/WO2007112940A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003060071A2 (en) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2004041863A2 (en) * | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
Non-Patent Citations (7)
Title |
---|
DOCKAL M ET AL: "The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 274, no. 41, 8 October 1999 (1999-10-08), pages 29303 - 29310, XP002990741, ISSN: 0021-9258 * |
FASANO M ET AL: "The extraordinary ligand binding properties of human serum albumin", IUBMB LIFE, TAYLOR AND FRANCIS, LONDON,, GB, vol. 57, no. 12, December 2005 (2005-12-01), pages 787 - 796, XP009090343, ISSN: 1521-6543 * |
GIBBS W W: "NANOBODIES", SCIENTIFIC AMERICAN, SCIENTIFIC AMERICAN INC., NEW YORK, NY, US, vol. 293, no. 2, August 2005 (2005-08-01), pages 67 - 71, XP001238880, ISSN: 0036-8733 * |
KRAGH-HANSEN U: "Structure and ligand binding properties of human serum albumin", DANISH MEDICAL BULLETIN, DANISH MEDICAL ASSOCIATION, COPENHAGEN, DK, vol. 37, no. 1, 1990, pages 57 - 84, XP009090324, ISSN: 0007-8916 * |
REVETS H ET AL: "NANOBODIES AS NOVEL AGENTS FOR CANCER THERAPY", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 5, no. 1, 2005, pages 111 - 124, XP009076361, ISSN: 1471-2598 * |
SMITH B J ET AL: "Prolonged in vivo residence times of antibody fragments associated with albumin", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 12, no. 5, September 2001 (2001-09-01), pages 750 - 756, XP002270731, ISSN: 1043-1802 * |
WANG W ET AL: "AlbuBNP, a Recombinant B-Type Natriuretic Peptide and Human Serum Albumin Fusion Hormone, as a Long-Term Therapy of Congestive Heart Failure", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 21, no. 11, November 2004 (2004-11-01), pages 2105 - 2110, XP003014318, ISSN: 0724-8741 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007112940A2 (en) | 2007-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007112940A3 (en) | Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same | |
PH12019500644A1 (en) | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections | |
WO2008074840A3 (en) | Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders | |
WO2009147248A3 (en) | Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases | |
WO2007104529A3 (en) | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling | |
WO2009095489A3 (en) | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling | |
MX2010005783A (en) | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same. | |
MX2009002816A (en) | Albumin fusion proteins. | |
WO2006131928A8 (en) | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis | |
AU2012257942A8 (en) | Amino acid sequences directed against IL-17A, IL-17F and/or IL17-A/F and polypeptides comprising the same | |
MY162737A (en) | 4-1bb binding molecules | |
WO2011106770A3 (en) | Modified proteins and methods of making and using same | |
AU2008338591A8 (en) | Binding molecules to the human OX40 receptor | |
UA100682C2 (en) | Antibody which neutralizes human cytomegalovirus (hcmv) and use thereof | |
WO2007056681A3 (en) | Methods for administering hypoglycemic agents | |
WO2007039903A3 (en) | Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis | |
WO2008143668A3 (en) | Indoleamine-2, 3-dioxygenase-2 | |
EP2274442A4 (en) | Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same | |
MY150226A (en) | Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use | |
WO2010142551A8 (en) | Amino acid sequences directed against receptors to cytokines belonging to the il-17 family | |
WO2009125409A3 (en) | Fatty acid amides and uses thereof | |
WO2009138494A3 (en) | Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors | |
WO2009035959A3 (en) | Radiofluorination methods | |
WO2008095622A3 (en) | SECRETED LUCIFERASE MLuc7 AND USE THEREOF | |
WO2009047634A3 (en) | Aqueous formulations of acetaminophen for injection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07723759 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07723759 Country of ref document: EP Kind code of ref document: A2 |